From: From animal models to human disease: a genetic approach for personalized medicine in ALS
Species | Mutation | Promoter | Age at onset (days) | Survival (days) | Phenotype | References | |||
---|---|---|---|---|---|---|---|---|---|
Paralysis | Cognitive symptoms | Neuropathological findings and particularities | Gliosis | ||||||
Mice | KO | n/a | nd | nd | nd | nd | 24Â h death, chromosomal abnormality, sterility | nd | [198] |
 | KO | n/a | nd | nd | nd | Y | No motor phenotype, hyperactivity behavior | nd | [199] |
 | hFUSWT | mPrp | 4 weeks | 10–13 weeks | Y | N | Tremors, weight loss, deficit in rotarod, increase cytoplasmic FUS signal, spinal MN loss, NMJ loss | Y | [200] |
 | hFUSWT, R521G | CAG | 10 | 30 | Na | Y | More lethality in FUSWT, no MN loss in lateral column, MA, NMJ loss, reduced social interaction and motor performance | Y | [201] |
Rats | hFUSWT, R521Cb | TRE | 27–48 | 33–55 | Y | Y | Few MN loss, MA, NMJ loss, ubiquitin inclusions, no FUS inclusions | Y | [202] |
Fruit flies | hFUSWT, R524S, P525L | OK371-Gal4 | nd | nd | nd | nd | Large MN, decreased locomotor function, NMJ loss | nd | [203] |
 | hFUSWT, R518K, R521C, R521H | OK371-Gal4/elav-GS | 10 | ~17 | nd | nd | Decreased locomotor function, no NMJ loss, more cytosolic FUS in mutant, | nd | [204] |
Nematodes | hFUSWT, R514G, R521G, R522G, P525L, FUS513, FUS501 | Prgef-1 | 3 | 8.1–9.7 | Y | nd | NCI of mutant FUS, worst phenotype in R522G, P525L, FUS513 and FUS501 | nd | [206] |
 | S57Δ | unc-47 | 12–13 | normal | Y | nd | MN loss, FUS insoluble aggregates | nd | [207] |
Zebrafish | R521C, R521H, S57Δ | mRNA | 48 hpf | nd | nd | nd | Reduced swimming at TEER, NMJ loss | nd |